Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKesson
Cerilliant
Covington
Medtronic
Daiichi Sankyo
Colorcon
Mallinckrodt
Merck

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,045,519

« Back to Dashboard

Summary for Patent: 9,045,519
Title:N-pyrazole A.sub.2A receptor agonists
Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. ##STR00001##
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/020,736
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,045,519

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,045,519

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,872 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
7,183,264 N-pyrazole A2A receptor agonists ➤ Sign Up
7,655,637 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
6,403,567 N-pyrazole A2A adenosine receptor agonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
US Army
Argus Health
Healthtrust
Julphar
Fuji
Boehringer Ingelheim
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.